nuclearMedicine

Who We Are 

Embracing and advancing state-of-the-art, highly effective medical technology, INITIO offers innovative molecular medicine to provide the best in diagnostic and therapeutic services. Taking the initiative to make change happen, we are a new beginning in medicine.

Our Commitment

Guided by information, knowledge and facts, we don’t just believe, we know.

We know that innovation is essential to progress;
That integrity is fundamental to excellence;
And that compassion is paramount.

Learn more About US

PET/CT

Currently, PET/CT scanning is a powerful but underused tool in B.C. and Canada.
INITIO, a private PET/CT clinic, is making this important diagnostic option more widely available within B.C. health care, thereby augmenting the public availability of PET/CT and its current restriction to cancer indications only.

PET/CT diagnostic scanning provides patients and their physicians an imaging option that offers further specialized insights into health problems, avoiding unnecessary, non-contributory imaging tests and procedures, and potentially leading to the avoidance of costly surgical or other therapeutic interventions.

Accurately informed with a PET/CT scan, with your physician, you can confidently take the next steps in making decisions about your health care.

Research

INITIO is built around individuals who value the integrity of pursuing knowledge and truth. To us, research is a key component in fostering a shared understanding of the ways in which PET/CT and theranostics can improve patient outcomes and wellbeing. It is integral to optimal patient management because it provides the evidence for effective interventions and for establishing that resources, whether public or personal, are used to achieve the best health outcomes.

Publicly Funded Uses of PET Scans in Canada

Sarah Garland and Andra Morrison

Summary

Positron emission tomography (PET) is a nuclear medical imaging tool. PET scanners require a cyclotron or a positron-emitting generator to manufacture the isotopes used in PET scans.1 PET represents a nuclear imaging alternative to single-photon emission computed tomography, or SPECT.1 Both technologies provide images of the structure and function…

Learn More

Prostate Cancer Patient Guide

Prostate Cancer Foundation

Summary

About this guide There are no two ways about it: getting diagnosed with cancer is hard and it is life-changing. Despite increasing optimism about treatment, today’s cancer landscape can be challenging as patients have access to an unprecedented amount of information. There are literally millions of cancer-related webpages, blogs, and videos available…

Learn More

The Use of Positron Emission Tomography (PET) for Cancer Care Across Canada

Susan D. Martinuk

Summary

Key Findings 1.1 Cancer is a Growing Challenge in Canada One out of every four Canadians will die from cancer. It is the leading cause of premature death in Canadians, and the number of cancer cases will increase each year as the Canadian population grows and ages. 1.2 PET Scans Can Play an Important Role in Cancer Detection and Diagnosis Studies have…

Learn More

Current status of theranostics in prostate cancer

Irene Virgolini, Clemens Decristoforo, Alexander Haug, Stefano Fanti, and Christian Uprimny

Summary

The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA radioligand therapy (PRLT) in castration-resistant (CR)PC is…

Learn More

Clinical Trials

Clinical trials provide the evidence for the most appropriate health interventions based upon a rigorous evaluation of their benefits (effectiveness, safety, quality of life, and costs and benefits of interventions). INITIO is actively seeking out and participating in clinical trials. Being a participant in a clinical trial offers you the opportunity to provide answers that may benefit not only you directly, but also others like you and generations of patients who will follow you.

These safe, government-approved trials help to improve on existing treatments and find new ones. They further research knowledge about disease and its treatment, and raise the quality of health care for every individual.

A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer’s Disease (Clarity AD)

Status

Study Description

This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study...

Sponsor

Eisai Inc.

Collaborator

Biogen

Learn More

68Ga-PSMA PET/CT in Prostate Cancer

Status

Enrolling by…

Study Description

The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PET/CT and as a diagnostic and decision making tool in the management prostate cancer patients...

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Collaborator

Sir Mortimer B. Davis - Jewish General Hospital

Learn More

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S2)

Status

Recruiting…

Study Description

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid...

Sponsor

Novartis Pharmaceuticals

Collaborator

Amgen, Banner Alzheimer's Institute

Learn More

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)

Status

Recruiting…

Study Description

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of…

Sponsor

Hoffmann-La Roche

Collaborator

Hoffmann-La Roche

Learn More

Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer’s Disease (LUCIDITY)

Status

Recruiting…

Study Description

The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day and 16 mg/day in the treatment of subjects with early Alzheimer's Disease compared to placebo...

Sponsor

TauRx Therapeutics Ltd

Collaborator

TauRx Therapeutics Ltd

Learn More

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S1)

Status

Recruiting…

Study Description

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype...

Sponsor

Novartis Pharmaceuticals

Collaborator

Banner Alzheimer's Institute, National Institute on Aging (NIA), Alzheimer's Association, Amgen

Learn More

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease (Mission AD1)

Status

Recruiting…

Study Description

The name of this trial is MissionAD1...

Sponsor

Eisai Co., Ltd.

Collaborator

Biogen

Learn More